Potential antileprotic agents. 3. Inhibition of mycobacterial dihydrofolic reductase by 2,4-diamino-5-methyl-6-alkylquinazolines.
D000900:Anti-Bacterial Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D003622:Dapsone / Q000494:pharmacology; D004357:Drug Synergism; D013293:Enterococcus faecalis / Q000187:drug effects; D004888:Erysipelothrix / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D005493:Folic Acid Antagonists; D008826:Microbial Sensitivity Tests; D009166:Mycobacterium leprae / Q000187:drug effects* / Q000201:enzymology; D011425:Propionibacterium acnes / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011799:Quinazolines / Q000138:chemical synthesis* / Q000494:pharmacology; D012475:Salmonella / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D005493:Folic Acid Antagonists; D011799:Quinazolines; D003622:Dapsone